Intracardiac angiotensin-converting enzyme inhibition improves diastolic function in patients with left ventricular

S P Friedrich1, B H Lorell, M F Rousseau

  • 1Charles A. Dana Research Institute, Boston, Mass.

Circulation
|December 1, 1994
PubMed

Insights

Intracoronary enalaprilat improved left ventricular (LV) diastolic function in patients with LV hypertrophy by enhancing chamber distensibility and regional relaxation. These benefits were not observed in patients with dilated cardiomyopathy, suggesting localized cardiac renin-angiotensin system activation in hypertrophy.

Area of Science:

  • Cardiology
  • Pharmacology
  • Physiology

Background:

  • Cardiac hypertrophy is linked to increased intracardiac angiotensin-converting enzyme activity, potentially causing diastolic dysfunction.
  • The role of the cardiac renin-angiotensin system in pressure-overload hypertrophy and diastolic dysfunction requires further elucidation.

Purpose of the Study:

  • To investigate the effects of intracoronary enalaprilat on left ventricular (LV) diastolic function in patients with LV hypertrophy due to aortic stenosis.
  • To compare the effects of enalaprilat on diastolic function in patients with LV hypertrophy versus dilated cardiomyopathy.

Main Methods:

  • Administered enalaprilat (0.05 mg/min) via left coronary artery infusion in patients with LV hypertrophy (n=20) and dilated cardiomyopathy (n=10).
  • Assessed LV pressure, dimensions, regional wall motion, and Doppler flow-velocity profiles.
  • Monitored systemic neurohormonal markers to ensure localized effects.

Main Results:

  • In aortic stenosis patients, enalaprilat reduced LV end-diastolic pressure and improved diastolic distensibility, relaxation, and filling in the perfused segments.
  • No systemic neurohormonal activation was observed.
  • Patients with dilated cardiomyopathy showed no improvement in diastolic function, despite a decrease in LV end-diastolic pressure, with accompanying changes in right atrial pressure.

Conclusions:

  • Intracoronary enalaprilat selectively improved LV diastolic function in patients with pressure-overload hypertrophy (aortic stenosis).
  • The absence of improvement in dilated cardiomyopathy suggests that the cardiac renin-angiotensin system is specifically activated in concentric hypertrophy.
  • These findings support the hypothesis of activated cardiac renin-angiotensin system contributing to diastolic dysfunction in concentric hypertrophy.
Abstract

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...